Actively Recruiting
Phase 2b Study Evaluating Doses of YMI024 for Reducing Inflammation in Adults With Stable Coronary Artery Disease and Elevated hsCRP
Led by Novartis Pharmaceuticals · Updated on 2026-10-15
180
Participants Needed
23
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug YMI024 in adults with stable coronary artery disease CAD who have persistent inflammation, indicated by high levels of high-sensitivity C-reactive protein hsCRP. This Phase 2b study aims to assess how well different doses of YMI024 reduce systemic inflammation, as well as to monitor the drugs safety, tolerability, and dose response compared to a placebo. Participants include those with CAD alone or CAD combined with heart failure or chronic kidney disease, and the study is designed to provide detailed subgroup analysis. Participants are randomly assigned to one of six groups in equal proportions, receiving one of five different doses of YMI024 or a matching placebo. All participants continue their stable standard-of-care therapies throughout the trial. The study is double-blinded, meaning neither the participants nor the study staff know who receives which treatment. Treatment is given alongside regular care, and dose effects and safety are assessed over approximately three months. During the study, participants will have their inflammatory markers, specifically IL-6 and hsCRP, measured at the start and around three months later to evaluate changes. Safety is monitored by tracking adverse events over about four months. Participants will undergo scheduled visits for assessments, including blood tests and clinical evaluations, while continuing their usual medical care. The total participation duration aligns with the treatment and follow-up periods to comprehensively assess both efficacy and safety.
CONDITIONS
Brief Title
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here